These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 33042651)

  • 41. Sodium-glucose Cotransporter 2 Inhibitors' Rise to the Backbone of Heart Failure Management: A Clinical Review.
    Rohant N; Kennedy JL
    Heart Int; 2021; 15(1):42-48. PubMed ID: 36277321
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Sodium-Glucose Cotransporter-2 Inhibitors (SGLT-2i) Reduce Hospitalization for Heart Failure Only and Have No Effect on Atherosclerotic Cardiovascular Events: A Meta-Analysis.
    Sinha B; Ghosal S
    Diabetes Ther; 2019 Jun; 10(3):891-899. PubMed ID: 30875065
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Do the SGLT-2 Inhibitors Offer More than Hypoglycemic Activity?
    Flores E; Santos-Gallego CG; Diaz-Mejía N; Badimon JJ
    Cardiovasc Drugs Ther; 2018 Apr; 32(2):213-222. PubMed ID: 29679303
    [TBL] [Abstract][Full Text] [Related]  

  • 44. SGLT-2 Inhibitors: The Next-generation Treatment for Type 2 Diabetes Mellitus.
    Lukic N; Macvanin MT; Gluvic Z; Rizzo M; Radak D; Suri JS; Isenovic ER
    Curr Med Chem; 2023 Oct; ():. PubMed ID: 37855338
    [TBL] [Abstract][Full Text] [Related]  

  • 45. SGLT-2 Inhibitors and Cardiovascular Risk in Diabetes Mellitus: A Comprehensive and Critical Review of the Literature.
    Imprialos K; Faselis C; Boutari C; Stavropoulos K; Athyros V; Karagiannis A; Doumas M
    Curr Pharm Des; 2017; 23(10):1510-1521. PubMed ID: 28120716
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Sodium glucose cotransporter (SGLT)-2 inhibitors: Do we need them for glucose-lowering, for cardiorenal protection or both?
    Scholtes RA; van Baar MJB; Lytvyn Y; Bjornstad P; Nieuwdorp M; Cherney DZI; van Raalte DH
    Diabetes Obes Metab; 2019 Apr; 21 Suppl 2(Suppl 2):24-33. PubMed ID: 30843294
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Sodium-glucose cotransporter 2 inhibitors and fracture risk in patients with type 2 diabetes mellitus: A systematic literature review and Bayesian network meta-analysis of randomized controlled trials.
    Azharuddin M; Adil M; Ghosh P; Sharma M
    Diabetes Res Clin Pract; 2018 Dec; 146():180-190. PubMed ID: 30389620
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Physiological monitoring of the complex multimorbid heart failure patient - diabetes and monitoring glucose control.
    Seferović PM; Jhund PS
    Eur Heart J Suppl; 2019 Dec; 21(Suppl M):M20-M24. PubMed ID: 31908611
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Sodium-Glucose Cotransporter-2 Inhibitors at Discharge from Cardiology Hospitalization Department: Decoding A New Clinical Scenario.
    Rozado J; García Iglesias D; Soroa M; Junco-Vicente A; Barja N; Adeba A; Vigil-Escalera M; Alvarez R; Torres Saura F; Capín E; García L; Rodriguez ML; Calvo D; Moris C; Delgado E; de la Hera JM
    J Clin Med; 2020 Aug; 9(8):. PubMed ID: 32796615
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cardiovascular Effects of Sodium-Glucose Cotransporter-2 Inhibitors in Adults With Type 2 Diabetes.
    Woo VC
    Can J Diabetes; 2020 Feb; 44(1):61-67. PubMed ID: 31839265
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Ertugliflozin: a sodium-glucose cotransporter-2 (SGLT-2) inhibitor for glycemic control in type 2 diabetes.
    Derosa G; Maffioli P
    Ther Clin Risk Manag; 2018; 14():1637-1640. PubMed ID: 30237717
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacoeconomic evaluation of sodium-glucose transporter-2 (SGLT2) inhibitors for the treatment of type 2 diabetes.
    Rahman W; Solinsky PJ; Munir KM; Lamos EM
    Expert Opin Pharmacother; 2019 Feb; 20(2):151-161. PubMed ID: 30412008
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Systematic review of metformin monotherapy and dual therapy with sodium glucose co-transporter 2 inhibitor (SGLT-2) in treatment of type 2 diabetes mellitus.
    Molugulu N; Yee LS; Ye YT; Khee TC; Nie LZ; Yee NJ; Yee TK; Liang TC; Kesharwani P
    Diabetes Res Clin Pract; 2017 Oct; 132():157-168. PubMed ID: 28797524
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of SGLT2 inhibitors on cardiovascular outcomes and mortality in type 2 diabetes: A meta-analysis.
    Zou CY; Liu XK; Sang YQ; Wang B; Liang J
    Medicine (Baltimore); 2019 Dec; 98(49):e18245. PubMed ID: 31804352
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The kidney and cardiovascular outcome trials.
    Bloomgarden Z
    J Diabetes; 2018 Feb; 10(2):88-89. PubMed ID: 29031006
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis.
    Wu JH; Foote C; Blomster J; Toyama T; Perkovic V; Sundström J; Neal B
    Lancet Diabetes Endocrinol; 2016 May; 4(5):411-9. PubMed ID: 27009625
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Oral Glucose-lowering Drugs and Cardiovascular Outcomes: From the Negative RECORD and ACCORD to Neutral TECOS and Promising EMPA-REG.
    Tsioufis C; Andrikou E; Thomopoulos C; Papanas N; Tousoulis D
    Curr Vasc Pharmacol; 2017; 15(5):457-468. PubMed ID: 27928947
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Emerging Roles of Sodium Glucose Cotransporter 2 (SGLT-2) Inhibitors in Diabetic Cardiovascular Diseases: Focusing on Immunity, Inflammation and Metabolism.
    Xie L; Xiao Y; Tai S; Yang H; Zhou S; Zhou Z
    Front Pharmacol; 2022; 13():836849. PubMed ID: 35295328
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Closing the knowledge gap on cardiovascular disease in type 2 diabetes: the EMPA-REG OUTCOME trial and beyond.
    Oral EA
    Drugs Context; 2016; 5():212299. PubMed ID: 27648101
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk.
    Erythropoulou-Kaltsidou A; Polychronopoulos G; Tziomalos K
    Diabetes Ther; 2020 Jan; 11(1):7-14. PubMed ID: 31734830
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.